Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA_(Emergency_Use_Authorization)
November 2020 |
| gptkbp:ATCCode |
gptkb:J06BD08
|
| gptkbp:CASNumber |
2423943-37-3
|
| gptkbp:combines |
etesevimab
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
bamlanivimab
|
| gptkbp:KEGGID |
D12074
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:macromoleculeType |
gptkb:IgG1_kappa
|
| gptkbp:mechanismOfAction |
neutralizes SARS-CoV-2 virus
|
| gptkbp:PubChem_CID |
gptkb:DB16335
145996610 |
| gptkbp:retired |
reduced efficacy against variants
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
dizziness anaphylaxis hypersensitivity |
| gptkbp:target |
gptkb:SARS-CoV-2_spike_protein
|
| gptkbp:UNII |
QKQ7B6Q1RL
|
| gptkbp:usedFor |
gptkb:COVID-19
|
| gptkbp:withdrawn |
gptkb:FDA
April 2021 |
| gptkbp:bfsParent |
gptkb:AbCellera
|
| gptkbp:bfsLayer |
7
|